Lexicon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) saw some unusual options trading on Friday. Stock investors acquired 2,504 call options on the stock. This represents an increase of 61% compared to the typical volume of 1,558 call options.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Leerink Partnrs cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Piper Sandler cut their target price on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Leerink Partners restated a “market perform” rating and set a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average target price of $3.67.

Lexicon Pharmaceuticals Stock Up 72.0 %

Shares of NASDAQ:LXRX traded up $0.25 during trading on Friday, hitting $0.60. The stock had a trading volume of 229,836,459 shares, compared to its average volume of 4,924,403. The company has a market capitalization of $147.25 million, a PE ratio of -0.79 and a beta of 1.04. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. The firm’s fifty day moving average is $0.61 and its 200 day moving average is $1.01. Lexicon Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $2.47.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $26.55 million during the quarter, compared to the consensus estimate of $6.48 million. Analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several hedge funds have recently bought and sold shares of LXRX. Bayesian Capital Management LP bought a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $31,000. RPO LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth approximately $33,000. Renaissance Technologies LLC bought a new position in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $38,000. Arizona State Retirement System boosted its holdings in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 16,136 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its stake in shares of Lexicon Pharmaceuticals by 60.3% in the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 24,615 shares during the last quarter. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.